chartexchange

MiNK Therapeutics Inc (INKT) Q1 2026 Earnings Call Highlights: Prolonged Survival in Gastric ...

GuruFocus | Nov 11, 2026 4:06 PM EST

MiNK Therapeutics Inc (INKT) pairs durable oncology survival data with a newly initiated randomized ARDS program, all while maintaining a disciplined cash runway of at least 12 months. Related Stocks: INKT ,

Read original article